Rivermark Medical
MILWAUKEE, WI · Information Technology · 9 employees
Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function.
Funding history
- Series series d — $20.0M — May 2026
- Series seed — $4.1M — Oct 2024
- Funding Round — $30.0M — Oct 2024
- Series series c — $30.0M — Oct 2024
- Series seed — $4.1M — Jul 2023
Recent signals
- May 13, 2026: Raised $20.0M in Series series d
- Oct 11, 2024: Raised $4.1M in Series seed
- Oct 11, 2024: Raised $30.0M
- Oct 10, 2024: Raised $30.0M in Series series c
- Jul 31, 2023: Raised $4.1M in Series seed
- Nov 19, 2021: Raised $1.8M in Series seed
See plans & pricing → Track Rivermark Medical’s funding, hiring, and signals — with verified contacts — on Fundz.